Trial Site Detail

 

Drug:
CB-839
Trial:
Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
Conditions: Solid Tumors
Trial Status:
Active, not recruiting

 

Columbia University - Herbert Irving Cancer Center

     
New York , NY 10032
USA

 

Principal Investigator:
Kevin Kalinsky, MD
Contact:
212-305-5098 hemoncnewpatients@columbia.edu
Activation Status of this Site:
Closed
Notes about this Site:
Columbia University - Herbert Irving Cancer Center Website:

 

 

Navigating the Map

Use the plus (+) and minus (-) controls to zoom in/out.

Click and drag the map or use the arrows to move (pan) the map.

Tip: Click the marker before zooming and the map will stay centered on the marker as you zoom.